Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1. The initial filing was made on April 23, 2024, and has since been amended. The company, headquartered in Dallas, Texas, seeks to have the registration become effective at 4:30 p.m. EDT on May 9, 2024. This request was communicated through a letter addressed to the SEC, specifically to Juan Grana of the Division of Corporation Finance, and signed by Jacob D. Cohen, Chairman and CEO of Mangoceuticals.

Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1. The initial filing was made on April 23, 2024, and has since been amended. The company, headquartered in Dallas, Texas, seeks to have the registration become effective at 4:30 p.m. EDT on May 9, 2024. This request was communicated through a letter addressed to the SEC, specifically to Juan Grana of the Division of Corporation Finance, and signed by Jacob D. Cohen, Chairman and CEO of Mangoceuticals.